Researcher
Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IdiSNA, Spain
Dr Esperanza Martin-Sanchez (BSc, PhD), researcher at Center for Applied Medical Research (CIMA Universidad de Navarra, Pamplona, Spain)
I was graduated in Biology at the University of Basque Country, and performed my PhD in Molecular Biology and Biomedicine at the Spanish National Cancer Research Center, one of the most prestigious centers for cancer research, in collaboration with the Marques de Valdecilla Research Institute and the MD Anderson Cancer Center. My PhD was focused on the identification of new potential therapeutic targets in chemoresistant lymphomas. During the postdoctoral stage at Navarrabiomed – Medical Research Institute of Navarra, I was involved in the identification of epigenetic biomarkers predictive of diagnosis, prognosis and response to treatment in breast and cervical tumors. Later, I joined the Center for Applied Medical Research – University of Navarra, and carried out improvised projects related with COVID-19 to identify immune biomarkers that detect high-risk patients and predict vaccine effectiveness, especially in patients with hematological cancer. In addition, I performed some preclinical studies in collaboration with pharmaceutical companies to understand the mechanisms and therapeutic efficacy of new antibodies in acute myeloblastic leukemia and multiple myeloma. I am currently working on the development of minimally-invasive methods, including circulating tumor cells, to detect early multiple myeloma.
My participation in 20 research projects granted in national (two as a principal investigator) and international calls has provided me with a wide expertise and knowledge in molecular and cellular biology of cancer, as observed in 19 research articles in high-impact journals, one book chapter, 50+ oral communications and poster in national and international conferences, supervision of one PhD and two MSc dissertations, and 30+ peer-reviews for scientific journals.